Please ensure Javascript is enabled for purposes of website accessibility

Why These Biotechs Are Soaring Today

By Brian Orelli, PhD - Nov 9, 2016 at 4:10PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors believe a Trump presidency is better for the biotech industry than a Clinton one would have been.

Image source: Getty Images.

What happened

Juno Therapeutics (JUNO), Vertex Pharmaceuticals (VRTX 1.23%), BioMarin Pharmaceutical (BMRN 1.41%), and Celgene (CELG) were all up at least 10% as of 2:58 p.m., after Donald Trump won the U.S. presidential election yesterday.

So what

Hilary Clinton had been quite vocal about high drug prices and her plans to do something about them, including spurring competition. Now that it's clear she won't be in the White House, investors have taken the risk of lower drug prices out of their valuations.

Vertex Pharmaceuticals' cystic fibrosis drugs and BioMarin Pharmaceuticals' orphan drugs have quite high prices, since they aren't used by very many patients. The prices of Celgene's cancer drugs are also pretty steep, but that's generally true of most cancer drugs. Juno Therapeutics doesn't have any therapies on the market yet, but since its cancer treatment is complex -- involving taking cells from patients, activating them, and then putting them back into the patient -- most investors expect it'll be quite expensive, likely priced higher than most cancer drugs.

Interestingly, both Celgene's and BioMarin's managements noted on their recent earnings conference calls that very little of their revenue growth came from price hikes. "Consistent with prior periods, our growth was predominantly volume-driven, as product volume grew 25%," noted Celgene's CFO Peter Kellogg of the 28% year-over-year growth in revenue.

"If there were any kind of regulation or policy around limiting the number or the amount of price increase one can implement every year or so, that would have zero impact on our business today, because that's not what we've been doing," said BioMarin's chairman and CEO Jean-Jacques Bienaime.

Based on today's move, investors clearly didn't buy Bienaime's zero-impact argument, perhaps because they were worried about other potential Clinton-sponsored mechanisms to lower drug prices beyond limiting further price hikes.

Now what

While a Trump presidency might be good for drugmakers, their long-term growth in revenue will come from increasing sales of their current drugs and developing new ones, no matter who is president. That's what investors should be focused on now that the election is over.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

BioMarin Pharmaceutical Inc. Stock Quote
BioMarin Pharmaceutical Inc.
BMRN
$79.28 (1.41%) $1.10
Celgene Corporation Stock Quote
Celgene Corporation
CELG
Vertex Pharmaceuticals Incorporated Stock Quote
Vertex Pharmaceuticals Incorporated
VRTX
$255.45 (1.23%) $3.10
Juno Therapeutics, Inc. Stock Quote
Juno Therapeutics, Inc.
JUNO

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
327%
 
S&P 500 Returns
116%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.